Skip to content
Pharma Observatory a Scientist.com platform

Condition (MeSH)

Uterine Diseases

ClinicalTrials.gov lists 4,383 trials for Uterine Diseases or a narrower condition beneath it. National Cancer Institute (NCI) has the most among industry and government lead sponsors, with 118.

MeSH D014591 Urogenital Diseases C12
Email me this page as a PDF

Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Phase 1 Phase 1 477 Phase 1/2 Phase 1/2 239 Phase 2 Phase 2 778 Phase 2/3 Phase 2/3 47 Phase 3 Phase 3 343 Phase 4 Phase 4 134 Not applicable Not applicable 1,315 Observational Observational 1,045 Phase 1 Phase 1 477 Phase 1/2 Phase 1/2 239 Phase 2 Phase 2 778 Phase 2/3 Phase 2/3 47 Phase 3 Phase 3 343 Phase 4 Phase 4 134 Not applicable Not applicable 1,315 Observational Observational 1,045

Trials per phase (log scale)

2 more sections with rows

61 of the 4,383 trials are tagged with Uterine Diseases itself; the rest are tagged with a narrower condition beneath it.

Get the Uterine Diseases report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

When did Uterine Diseases trials start? (36)

Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year. 13 trials are registered to start in 2027 or later, and not listed here.

Trials over time, by phase

  • Phase 1
  • Phase 1/2
  • Phase 2
  • Phase 2/3
  • Phase 3
  • Phase 4
  • Not applicable
  • Observational
  • Other (Unknown)

Top of scale: 323

1990: 1 trials (Observational 1) 1992: 3 trials (Observational 1, Phase 3 1, Phase 2 1) 1993: 2 trials (Phase 3 1, Phase 2 1) 1994: 4 trials (Observational 2, Phase 3 1, Phase 2 1) 1995: 4 trials (Observational 1, Phase 3 1, Phase 2 1, Phase 1 1) 1996: 10 trials (Not applicable 1, Phase 3 3, Phase 2 5, Phase 1 1) 1997: 14 trials (Not applicable 1, Phase 3 5, Phase 2 8) 1998: 22 trials (Observational 2, Not applicable 3, Phase 3 3, Phase 2 11, Phase 1 3) 1999: 26 trials (Observational 7, Not applicable 2, Phase 3 5, Phase 2 4, Phase 1/2 2, Phase 1 6) 2000: 38 trials (Observational 9, Not applicable 3, Phase 3 7, Phase 2 15, Phase 1/2 1, Phase 1 3) 2001: 42 trials (Observational 5, Not applicable 3, Phase 4 1, Phase 3 5, Phase 2 16, Phase 1/2 5, Phase 1 7) 2002: 45 trials (Observational 9, Not applicable 1, Phase 4 1, Phase 3 15, Phase 2 16, Phase 1 3) 2003: 62 trials (Observational 15, Not applicable 9, Phase 4 2, Phase 3 9, Phase 2 15, Phase 1/2 6, Phase 1 6) 2004: 62 trials (Observational 15, Not applicable 7, Phase 4 3, Phase 3 7, Phase 2 21, Phase 1/2 3, Phase 1 6) 2005: 75 trials (Observational 16, Not applicable 17, Phase 4 3, Phase 3 8, Phase 2/3 2, Phase 2 18, Phase 1/2 2, Phase 1 9) 2006: 100 trials (Observational 17, Not applicable 25, Phase 4 3, Phase 3 16, Phase 2 27, Phase 1/2 2, Phase 1 10) 2007: 105 trials (Observational 22, Not applicable 21, Phase 4 6, Phase 3 14, Phase 2 29, Phase 1/2 3, Phase 1 10) 2008: 99 trials (Observational 25, Not applicable 27, Phase 4 2, Phase 3 12, Phase 2/3 1, Phase 2 20, Phase 1/2 2, Phase 1 10) 2009: 104 trials (Observational 30, Not applicable 17, Phase 4 6, Phase 3 17, Phase 2/3 2, Phase 2 21, Phase 1/2 2, Phase 1 9) 2010: 110 trials (Other 1, Observational 27, Not applicable 30, Phase 4 11, Phase 3 6, Phase 2/3 1, Phase 2 15, Phase 1/2 5, Phase 1 14) 2011: 131 trials (Observational 26, Not applicable 39, Phase 4 6, Phase 3 15, Phase 2/3 1, Phase 2 24, Phase 1/2 1, Phase 1 19) 2012: 125 trials (Observational 29, Not applicable 57, Phase 4 2, Phase 3 9, Phase 2 15, Phase 1/2 4, Phase 1 9) 2013: 108 trials (Observational 28, Not applicable 41, Phase 4 8, Phase 3 6, Phase 2/3 1, Phase 2 12, Phase 1/2 4, Phase 1 8) 2014: 130 trials (Observational 32, Not applicable 53, Phase 4 3, Phase 3 9, Phase 2 16, Phase 1/2 9, Phase 1 8) 2015: 159 trials (Observational 28, Not applicable 58, Phase 4 4, Phase 3 14, Phase 2/3 2, Phase 2 27, Phase 1/2 9, Phase 1 17) 2016: 165 trials (Observational 38, Not applicable 71, Phase 4 7, Phase 3 10, Phase 2 17, Phase 1/2 11, Phase 1 11) 2017: 189 trials (Observational 48, Not applicable 56, Phase 4 7, Phase 3 14, Phase 2/3 4, Phase 2 30, Phase 1/2 11, Phase 1 19) 2018: 195 trials (Observational 34, Not applicable 67, Phase 4 6, Phase 3 16, Phase 2/3 5, Phase 2 33, Phase 1/2 11, Phase 1 23) 2019: 238 trials (Observational 64, Not applicable 69, Phase 4 6, Phase 3 15, Phase 2 35, Phase 1/2 11, Phase 1 38) 2020: 254 trials (Observational 63, Not applicable 78, Phase 4 7, Phase 3 14, Phase 2/3 4, Phase 2 39, Phase 1/2 19, Phase 1 30) 2021: 283 trials (Observational 74, Not applicable 86, Phase 4 7, Phase 3 20, Phase 2/3 3, Phase 2 45, Phase 1/2 19, Phase 1 29) 2022: 261 trials (Observational 70, Not applicable 69, Phase 4 5, Phase 3 18, Phase 2/3 9, Phase 2 37, Phase 1/2 16, Phase 1 37) 2023: 293 trials (Observational 82, Not applicable 90, Phase 4 7, Phase 3 8, Phase 2/3 3, Phase 2 42, Phase 1/2 26, Phase 1 35) 2024: 323 trials (Observational 101, Not applicable 94, Phase 4 4, Phase 3 15, Phase 2/3 4, Phase 2 50, Phase 1/2 18, Phase 1 37) 2025: 308 trials (Observational 71, Not applicable 109, Phase 4 7, Phase 3 10, Phase 2/3 4, Phase 2 53, Phase 1/2 20, Phase 1 34)

Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.

Trials started per year
Year Trials started
2026 (partial year) 257
2025 308
2024 323
2023 293
2022 261
2021 283
2020 254
2019 238
2018 195
2017 189

Showing 10 of 36 earlier years.

Start your 14-day trial Email me all 36 earlier years as a PDF

Forecast of the full-year count, planned starts included, not rows of this table: about 300 trials starting in 2026 and about 300 in 2027, the average of the 24 months through September, counted as registered and carried forward. The rows of this table count trials registered so far with a start date in the year, planned starts included; the forecast looks ahead to the count for the whole year, so it is not the same measure. In backtests on conditions of this size, forecasts made part-way through the year were typically off by about 13 percent and ran about 12 percent low against the count later registered; forecasts made before the year began were off by about 19 percent and ran about 17 percent low against the count later registered, and had about the same error as repeating last year's count. These figures rest on a few years of history (target years from 2018 to 2025, varying by figure), place each condition as it is mapped today rather than as it was then, and score against a count for the newest year that was still being revised. Only condition series were scored.

Prediction, not a registry value: median of 36 months from start to primary completion across 604 trials still running at the 2026-10-09 snapshot; registered median of 30 months across 2,249 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.

What phase are Uterine Diseases trials in? (10)

Shown in this order: phase order.

Show the trials by phase as a table
Trials by phase
Phase Trials
Phase 1 477
Phase 1/2 239
Phase 2 778
Phase 2/3 47
Phase 3 343
Phase 4 134
Not applicable 1,315
Observational 1,045
Expanded access 4
Unknown 1

How many Uterine Diseases trials are recruiting? (12)

Shown in this order: the order a trial moves through, from not yet recruiting to unknown.

Trials by recruitment status
Status Trials
Not yet recruiting 264
Recruiting 716
Enrolling by invitation 30
Active, not recruiting 259
Available 2

Showing 5 of 12 statuses.

Start your 14-day trial Email me all 12 statuses as a PDF

Status as registered on ClinicalTrials.gov. Each trial is counted once.

Which lead sponsors run the most Uterine Diseases trials? (5)

Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.

Lead sponsors
Sponsor Trials
National Cancer Institute (NCI) 118
Gynecologic Oncology Group 64
GlaxoSmithKline 56
Merck Sharp & Dohme LLC 39
Tata Memorial Hospital 28

Which drugs are being tested for Uterine Diseases? (4)

Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.

Drugs tested
Drug Trials
(nab)-paclitaxel 148
PEMBROLIZUMAB 110
TOPOTECAN 31
NIVOLUMAB 24

Interventions as named in the registry (11)

Shown in this order: most trials first.

Interventions as named in the registry
Drug Trials
Cisplatin 1 180
or carboplatin 113
Bevacizumab 1 56
Radiation Therapy 50
Brachytherapy 50

Showing 5 of 11 interventions.

Start your 14-day trial Email me all 11 interventions as a PDF

These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.

Which serious adverse events do Uterine Diseases trials report? (10)

Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.

Serious adverse events in this condition's trials
Adverse event Subjects affected Trials
Abortion/Gynecological conditions 639 1
Urinary tract infection 429 77
Vomiting 371 110
Abdominal pain 335 94
Abortion spontaneous incomplete 307 11

Showing 5 of 10 adverse events.

Start your 14-day trial Email me all 10 adverse events as a PDF

Which publications cover Uterine Diseases? (311)

Shown in this order: major-topic papers first, then newest, then most linked to trials.

Publications
Publication Journal Year Major topic
A Comparative Study on the Efficacy of Subendometrial Versus Intrauterine Platelet-Rich Plasma Injections for Treating Intrauterine Adhesions: A Retrospective Cohort Study. Journal of minimally invasive gynecology 2025 Yes
Current surgical treatment of uterine isthmocele: an update of existing literature. Archives of gynecology and obstetrics 2025 Yes
The Pivotal role of hysteroscopy in diagnosing subtle uterine lesions in infertile patients: Seeing the unseen can make the difference. European journal of obstetrics, gynecology, and reproductive biology 2025 Yes
Comparison of single-site and three-port hysterectomy for benign uterine diseases: A randomised trial (LESS-H). European journal of obstetrics, gynecology, and reproductive biology 2025 Yes
Isthmic uterine lesions: a comprehensive pictorial review of MRI features and management strategies. Abdominal radiology (New York) 2025 Yes

Showing 5 of 311 publications.

Start your 14-day trial Email me the first 50 publications as a PDF

Sub-conditions in MeSH (10)

MeSH descendants one level down with at least one trial, most trials first.

Not on this page

Not measured: delivery record.

Checked, with nothing recorded for this condition: prevalence and rare-disease identity.

Browse all condition evidence pages